New research from the CWMH.
Women are twice as likely as men to have major depressive disorder (MDD) during their lifetimes, and women are particularly at risk during the menopausal transition (including perimenopause and early menopause), which can last many [...]
Allopregnanolone is all over the place these days. We have seen several different allopregnanolone derivatives being used to treat postpartum depression (PPD). Last year, intravenous brexanolone (Zulresso) was approved by the FDA as the first [...]
In 2008, the National Institutes of Health funded the Menopause Strategies: Finding Lasting Answers for Symptoms and Health or MSFlash clinical trials network. The primary goal of MSFlash has been to find and test new [...]
Uguz and colleagues present data that indicate, in a group of women with panic disorder, neonatal outcomes were worse in the women who did not get treatment. This week’s roundup also features a lot of [...]
The newer “atypical” or second-generation antipsychotic agents are now used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders. The National Pregnancy Registry for Atypical Antipsychotics [...]
Recent studies have demonstrated that more than 10% of women experience clinically significant symptoms of anxiety during pregnancy, particularly during the first trimester. Anxiety during pregnancy is not necessarily a benign event. Various studies indicate [...]
Menstrual irregularities, including amenorrhea, are common among women with eating disorders. Given the menstrual abnormalities, there has been concern that women with eating disorders might be less likely to conceive naturally. A recent study has [...]
Research has suggested a relationship between the age at which a woman goes through menopause and her general cognitive functioning, specifically that better cognitive function is observed in women who enter into menopause at a [...]
Following the release of the MGH Perinatal Depression Scale (MGHPDS) on the App Store this past August, we are pleased to announce that the MGHPDS is now available for Android devices on the Google [...]
The use of the newer “atypical” or second-generation antipsychotic (SGA) agents continues to increase. These medications are used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and anxiety disorders. [...]